AI Engines For more Details: Perplexity Kagi Labs You
Antihistamine Action: Pheniramine maleate works by blocking the action of histamine, a chemical released by the body during allergic reactions. By inhibiting histamine receptors, it helps relieve symptoms such as itching, sneezing, runny nose, and watery eyes.
Allergic Rhinitis: Pheniramine maleate is commonly used to alleviate symptoms of allergic rhinitis, including nasal congestion, itching, sneezing, and runny nose caused by environmental allergens such as pollen, dust mites, or pet dander.
Conjunctivitis: It may also help relieve symptoms of allergic conjunctivitis, such as redness, itching, and watering of the eyes, by blocking histamine receptors in the eye tissues.
Common Cold: Pheniramine maleate is often included in over-the-counter cold and flu medications to alleviate symptoms such as sneezing, runny nose, and congestion associated with the common cold.
Cough Suppression: In combination with other ingredients, pheniramine maleate may help suppress coughing associated with the common cold or allergies.
Sedation: Pheniramine maleate has sedative effects and can cause drowsiness in some individuals. It is often included in nighttime cold and flu medications to help relieve symptoms and promote sleep.
Adverse Effects: Common side effects of pheniramine maleate may include drowsiness, dizziness, dry mouth, blurred vision, constipation, and urinary retention. Individuals should use caution when performing tasks that require mental alertness, such as driving or operating machinery, until they know how the medication affects them.
Avoiding Alcohol: Alcohol consumption should be avoided while taking pheniramine maleate, as it can increase the risk of drowsiness and other central nervous system depressant effects.
Interactions: Pheniramine maleate may interact with other medications, including sedatives, tranquilizers, and monoamine oxidase inhibitors (MAOIs). Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.
Special Populations: Caution should be exercised when administering pheniramine maleate to older adults, children, and individuals with certain medical conditions such as glaucoma, enlarged prostate, urinary retention, asthma, or chronic obstructive pulmonary disease (COPD).
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | -0.3 | |
ADHD | 2.4 | 0.2 | 11 |
Age-Related Macular Degeneration and Glaucoma | 0.3 | 0.1 | 2 |
Allergic Rhinitis (Hay Fever) | 0.7 | 1.4 | -1 |
Allergies | 2.6 | 1.1 | 1.36 |
Allergy to milk products | 0.8 | 0.5 | 0.6 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 1.2 | 2.5 | -1.08 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.4 | 2.25 |
Ankylosing spondylitis | 2.2 | 0.2 | 10 |
Anorexia Nervosa | 0.1 | 0.7 | -6 |
Antiphospholipid syndrome (APS) | 1 | 1 | |
Asthma | 0.5 | 0.4 | 0.25 |
Atherosclerosis | 0.5 | 0.9 | -0.8 |
Atrial fibrillation | 1.6 | 1 | 0.6 |
Autism | 4.9 | 4.1 | 0.2 |
Barrett esophagus cancer | 0.3 | 0.3 | 0 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.5 | 0.6 | -0.2 |
Brain Trauma | 0.5 | 0.3 | 0.67 |
Carcinoma | 1.6 | 1.2 | 0.33 |
Celiac Disease | 1.4 | 1.8 | -0.29 |
Cerebral Palsy | 1.1 | 0.3 | 2.67 |
Chronic Fatigue Syndrome | 2.6 | 2.9 | -0.12 |
Chronic Kidney Disease | 0.9 | 0.7 | 0.29 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 0.3 | 3 |
Chronic Urticaria (Hives) | 1.3 | 0.6 | 1.17 |
Coagulation / Micro clot triggering bacteria | 0.9 | 0.4 | 1.25 |
Colorectal Cancer | 1.6 | 0.6 | 1.67 |
Constipation | 0.5 | 0.1 | 4 |
Coronary artery disease | 0.3 | 0.5 | -0.67 |
COVID-19 | 4.9 | 5.2 | -0.06 |
Crohn's Disease | 2.8 | 1.9 | 0.47 |
cystic fibrosis | 0.5 | 0.6 | -0.2 |
deep vein thrombosis | 0.5 | 0.4 | 0.25 |
Depression | 5.3 | 3.9 | 0.36 |
Dermatomyositis | 0.3 | 0.3 | 0 |
Eczema | 0.4 | 1.1 | -1.75 |
Endometriosis | 1.8 | 0.4 | 3.5 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 1.5 | 0.7 | 1.14 |
Fibromyalgia | 0.7 | 1.4 | -1 |
Functional constipation / chronic idiopathic constipation | 3.1 | 2.7 | 0.15 |
gallstone disease (gsd) | 1 | 0.4 | 1.5 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.3 | 1.33 |
Generalized anxiety disorder | 0.5 | 1.5 | -2 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.2 | -0.2 | |
Graves' disease | 0.8 | 0.6 | 0.33 |
Halitosis | 0.5 | 0.3 | 0.67 |
Hashimoto's thyroiditis | 1.3 | 0.5 | 1.6 |
Hidradenitis Suppurativa | 0.3 | 0.3 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.9 | 0.3 | 5.33 |
hypercholesterolemia (High Cholesterol) | 0.4 | 0 | 0 |
hyperglycemia | 0.2 | 0.7 | -2.5 |
Hyperlipidemia (High Blood Fats) | 0.5 | 0.2 | 1.5 |
hypersomnia | 0 | 0 | |
hypertension (High Blood Pressure | 1.3 | 2.6 | -1 |
Hypothyroidism | 0.5 | -0.5 | |
Hypoxia | 0.3 | 0.3 | |
IgA nephropathy (IgAN) | 1.6 | -1.6 | |
Inflammatory Bowel Disease | 1.8 | 3.3 | -0.83 |
Insomnia | 0.5 | 0.3 | 0.67 |
Intelligence | 0.4 | 0.3 | 0.33 |
Intracranial aneurysms | 0.3 | 0.2 | 0.5 |
Irritable Bowel Syndrome | 2.5 | 1.8 | 0.39 |
Liver Cirrhosis | 2.2 | 1.9 | 0.16 |
Long COVID | 3.6 | 3.4 | 0.06 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.8 | 0.3 | 1.67 |
ME/CFS with IBS | 1 | 1.3 | -0.3 |
ME/CFS without IBS | 0.7 | 1.3 | -0.86 |
Menopause | 1.7 | 1.7 | |
Metabolic Syndrome | 3.9 | 3.9 | 0 |
Mood Disorders | 6.8 | 3.9 | 0.74 |
multiple chemical sensitivity [MCS] | 0.6 | 0 | 0 |
Multiple Sclerosis | 2.1 | 2.3 | -0.1 |
Multiple system atrophy (MSA) | 0.9 | 0.3 | 2 |
Neuropathy (all types) | 0.3 | 0.2 | 0.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 2.1 | -0.5 |
NonCeliac Gluten Sensitivity | 0.3 | -0.3 | |
Obesity | 4.6 | 1.5 | 2.07 |
obsessive-compulsive disorder | 2.9 | 1.8 | 0.61 |
Osteoarthritis | 0.9 | 0.9 | |
Osteoporosis | 0.9 | 0.3 | 2 |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 1.5 | 1.6 | -0.07 |
Polycystic ovary syndrome | 0.9 | 0.8 | 0.13 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.5 | -1.5 |
Premenstrual dysphoric disorder | 0.5 | 0.1 | 4 |
primary biliary cholangitis | 0.2 | 0.2 | 0 |
Psoriasis | 2.6 | 1.1 | 1.36 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.6 | 2.2 | 0.18 |
Rosacea | 0.7 | 0.4 | 0.75 |
Schizophrenia | 3.6 | 0.8 | 3.5 |
scoliosis | 0.2 | 0.2 | |
Sjögren syndrome | 1.8 | 1.5 | 0.2 |
Sleep Apnea | 0.5 | 0.5 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | 0 |
Stress / posttraumatic stress disorder | 1.5 | 1.1 | 0.36 |
Systemic Lupus Erythematosus | 1.6 | 0.6 | 1.67 |
Tic Disorder | 0.3 | 1 | -2.33 |
Tourette syndrome | 0 | 0.2 | 0 |
Type 1 Diabetes | 1.8 | 1.4 | 0.29 |
Type 2 Diabetes | 3.8 | 2.8 | 0.36 |
Ulcerative colitis | 1.8 | 2.3 | -0.28 |
Unhealthy Ageing | 2.8 | 0.9 | 2.11 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.